Clinical Trials Sponsored by Nordic Bioscience A/S

Total 1540 results

Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes (onset® 4)

Diabetes | Diabetes Mellitus, Type 1

United States, Germany
Novo Nordisk A/S

Completed

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Italy, United Kingdom, France, Serbia, Germany, South Africa, Canada, Ukraine, United Arab Emirates
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes (LIRA-Ramadan™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Malaysia, South Africa, Algeria, Lebanon, United Arab Emirates
Novo Nordisk A/S

Completed

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B (paradigm™ 3)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania
Novo Nordisk A/S

Completed

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Terminated

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers

Obesity | Metabolism and Nutrition Disorder

Netherlands
Novo Nordisk A/S

Completed

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Austria, Spain, Poland, United Kingdom, Croatia, Germany, Malaysia, Australia, France, Israel, Thailand, Ukraine, Turkey
Novo Nordisk A/S

Completed

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Diabetes Mellitus, Type 1

United Kingdom, Denmark, Sweden, Netherlands, Belgium, Finland, France, Australia, Ireland, Norway
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

Congenital Bleeding Disorder | Glanzmann's Disease

Japan
Novo Nordisk A/S

Completed

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes (DIET™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Slovakia, Germany, Argentina, Serbia, Poland, Russian Federation, Slovenia, Spain, Turkey
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Inflammation | Crohn's Disease

United States, Spain, Bulgaria, Czech Republic, Poland, Slovakia
Novo Nordisk A/S

Terminated

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

Diabetes | Diabetes Mellitus, Type 1

United Kingdom, United States, Switzerland, France, Germany, Canada
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BOOST™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico, Russian Federation, United Kingdom, Denmark, France, Israel, Australia, Romania
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)

Congenital Bleeding Disorder | Haemophilia A

United States, Macedonia, The Former Yugoslav Republic of, Serbia, Malaysia, Brazil, Turkey, Lithuania, Russian Federation, Italy, Japan, Poland, Puerto Rico, Taiwan
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of Levemir® in Diabetes (PREDICTIVE™)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Israel, Korea, Republic of, Turkey, Italy, Belgium, United Kingdom, Greece, Ireland, Sweden, Denmark, Finland, France, Czech Republic
Novo Nordisk A/S

Terminated

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Novo Nordisk A/S

Completed

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (TITRATE™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

India, Korea, Republic of, China
Novo Nordisk A/S

Completed

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-6)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Denmark, Sweden, Austria, Germany, Macedonia, The Former Yugoslav Republic of, Slovenia, France, Switzerland, Norway, Spain, Ireland, Finland, Romania
Novo Nordisk A/S

Completed

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Puerto Rico, United Kingdom, Ireland, Germany, Slovenia, Canada, France, Italy, Spain, Netherlands, Slovakia, Romania, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Germany, Netherlands, Argentina, Finland, Serbia, Mexico
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Terminated

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c (LEAD-3)

Diabetes Mellitus, Type 2 | Diabetes

United States, Mexico, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together (LEAD-2)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia, India, Italy, Russian Federation, Spain, Denmark, United Kingdom, Sweden, Belgium, Ireland, Argentina, Hungary, Norway, South Africa, Germany, Croatia, Netherlands, Bulgaria, Australia, Romania
Novo Nordisk A/S

Completed

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Spain, Finland, Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, United Kingdom, Ireland, France, South Africa, Ukraine
Novo Nordisk A/S

Completed

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Netherlands, Hungary, France, Bulgaria, Canada, Romania
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

India, Italy, United Kingdom, Finland, Japan, Argentina, Macedonia, The Former Yugoslav Republic of, Brazil
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Sweden, Norway, Germany, Australia
Novo Nordisk A/S

Completed

A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Delivery Systems

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Argentina, Turkey, Canada, South Africa, Mexico
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial

Menopause | Postmenopausal Vaginal Atrophy
Novo Nordisk A/S

Completed

Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

Cancer | Ovarian Cancer

Germany, France
Novo Nordisk A/S

Completed

Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark

Clinical Trials Sponsored by Nordic Bioscience A/S

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations